The financing will support the advancement of proprietary in vivo reprogramming therapies through pre-clinical translation.
"We are delighted to receive the continued support of Astellas Venture Management, Parkwalk Advisors and other existing investors as we relentlessly focus on progressing our novel pipeline of in vivo reprogramming therapies through pre-clinical translation. Aligned to a consolidated corporate structure and vision, this latest funding will provide sufficient cash runway to enable the achievement of key development milestones in both our internal programs as well as those being developed in collaboration with strategic partners. Existing investor commitment is a testament to our delivery of world-class science, expertise in cellular reprogramming and the unique potential of the MOGRIFY platform to deliver novel regenerative medicines to improve the lives of a broad spectrum of patients."
The financing round was led by Index Ventures with backing from Bessemer Venture Partners and Visionaries Club.
"Apron puts itself in the position of all these users – accountants, business owners and suppliers – and instead of trying to solve business payments from just one perspective, we create a town square where they can all come together to move money as smoothly as possible. We want to flip payments from being a blocker to being a booster: something that can be done quickly, securely and even give you a sense of joy and satisfaction."
Sartorius took a minority shareholding in the London startup through its corporate venture unit to support product commercialisation.
"The SPARTA platform will help customers optimize the design of nanoparticles at an early stage, even before the drug candidates move on to the clinic. We have teamed up to bring additional product commercialization and application expertise to the table to facilitate a swift transitioning from prototype to launch,"
— Oscar-Werner Reif, Head of Corporate Research and CTO
Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.
"GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments."
The financing round was led by Silverstripe Investment Management to support the rollout of fixed rate mortgage products.
"This successful fundraise, set against the backdrop of a challenging fundraising market is a clear testament to the strength of our unique approach and the significant opportunity to reimagine the structure of the UK mortgage market."
